A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs GMI 1359 (Primary)
  • Indications Cancer; Haematological malignancies
  • Focus Adverse reactions; First in man
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 11 Jul 2017 Planned number of patients changed from 20 to 60.
    • 11 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
    • 11 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top